New Metabolic Disease Articles from our Partners at Consultant 360

The Obesity Paradox: How Does It Affect Patients With Diabetes?

A new study, presented at the 2020 American Diabetes Association Scientific Sessions, adds to growing evidence of a so-called “obesity paradox” among patients hospitalized for diabetes.

https://www.consultant360.com/exclusive/endocrinology/ada/obesity-paradox-how-does-it-affect-patients-diabetes

Could Cinnamon Prevent Diabetes Progression?

While cinnamon has been shown to have glucose-lowering properties, whether these could be employed in patients with prediabetes to prevent disease progression is unknown.

https://www.consultant360.com/exclusive/endocrinology/diabetes/could-cinnamon-prevent-diabetes-progression

Parag Goyal, MD, MSc, on How a New Risk Calculator Can Reduce CV Readmission After a Heart Failure Hospitalization

Researchers recently examined the association between cardiac comorbidities and cardiovascular (CV) readmission among patients who had been hospitalized for heart failure. In doing so, the researchers developed a simple cardiac comorbidity count that was found to be independently associated with an increased risk for CV readmission. In this podcast, Parag Goyal, MD, MSc, provides an overview of the risk calculator and explains how it can play a role in meeting the “need to move toward a more tailored, personalized approach” to postdischarge therapy.

https://www.consultant360.com/podcast/cardiology/heart-failure/parag-goyal-md-msc-how-new-risk-calculator-can-reduce-cv

Simple Grip Test Could Predict Diabetes Risk

In a recent study, researchers investigated the possibility of using grip strength tests in the screening of patients for type 2 diabetes mellitus.

https://www.consultant360.com/exclusive/endocrinology/diabetes/simple-grip-test-could-predict-diabetes-risk

SGLT2 Inhibitor Improves HbA1c and More in T2D and Overweight, Obesity

In an analysis of 3 placebo-controlled, randomized, Phase 3 studies of a selective SGLT2 inhibitor, researchers observed clinically meaningful decreases in glycated HbA1c, fasting plasma glucose, and more compared with placebo.

https://www.consultant360.com/exclusive/endocrinology/diabetes/sglt2-inhibitor-improves-hba1c-and-more-t2d-and-overweight-obesity